Related Experiment Videos
Anti-Jo-1 antibodies.
Sandra Zampieri1, Anna Ghirardello, Luca Iaccarino
1Department of Medical and Surgical Science Division of Rheumatology, University of Padova, Italy.
Autoimmunity
|April 5, 2005
Summary
Anti-Jo-1 antibody, a marker for idiopathic inflammatory myopathies (IIM), targets histidyl-tRNA synthetase. Its detection aids in diagnosing IIM and monitoring disease activity.
Area of Science:
- Immunology
- Rheumatology
- Molecular Biology
Background:
- Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by muscle inflammation.
- Anti-Jo-1 autoantibodies are specific to certain subtypes of IIM, particularly polymyositis (PM) and dermatomyositis (DM).
- The target antigen for Anti-Jo-1 antibodies is histidyl-tRNA synthetase, an enzyme crucial for protein synthesis.
Observation:
- Anti-Jo-1 antibodies are prevalent in 20-30% of PM patients and 60-70% of those with interstitial pulmonary fibrosis.
- While found in DM, Anti-Jo-1 antibodies are less common than in PM and rare in pediatric cases or other connective tissue diseases.
- Highly sensitive and specific detection methods like ELISA, CIE, and immunoblotting are available for Anti-Jo-1 antibodies.
Findings:
- Anti-Jo-1 antibody is a specific biomarker for diagnosing and classifying IIM.
- Serum levels of Anti-Jo-1 antibodies correlate strongly with disease activity.
- Detection of Anti-Jo-1 antibodies is valuable for disease monitoring.
Implications:
- Early and accurate diagnosis of IIM can be improved through Anti-Jo-1 antibody testing.
- Monitoring Anti-Jo-1 antibody levels can guide treatment adjustments and predict disease course.
- Understanding the role of Anti-Jo-1 antibodies enhances knowledge of IIM pathogenesis.